![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EFPIA Vows to Reduce Delays in Getting Drugs to European Countries
EFPIA Vows to Reduce Delays in Getting Drugs to European Countries
April 14, 2022
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has pledged to look for ways to increase the availability of innovative medicines in European countries by reducing regulatory delays.
The pharma organization concluded that there are numerous factors that impact the time difference between European marketing authorization and the availability of a medicine within a specific state, including the speed of the regulatory review process.
The group noted, for example, that the average time it takes new drugs to gain reimbursement in the EU and in European Economic Area countries is 511 days, though the times vary considerably, from an average of 133 days in Germany to an average of 899 days in Romania.
Upcoming Events
-
21Oct